Physician

Oncology

Dr. Minetta Liu, MD

Minetta works in the field of Oncology. Minetta is a published doctor as well. She has 21 publications published. The latest was: Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. She accepts Medicare payments and is listed with Medicare.gov.

Publications

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast C...
Significance of Circulating Tumor Cells in metastatic triple negative breast Cancer patients within a randomized, phase II trial: TBCRC 019.
Detection of circulating tumor cells in high-risk endometrial Cancer.
The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer.
Circulating tumor cell analysis in metastatic triple-negative breast Cancers.
By the Numbers: Does Circulating Tumor Cell Enumeration Have a Role in Metastatic Breast Cancer?
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast Cancer brain metastases.
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer.
Narrowing racial gaps in breast Cancer chemotherapy initiation: the role of the patient-provider relationship.
Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials.
Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development.
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast Cancer.
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast Cancer.
Fibromatosis of the Breast after mammary prosthesis implantation.
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast Cancer.
Real-time imaging and characterization of human Breast tissue by reflectance confocal microscopy.
Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity.
Antiestrogens, aromatase inhibitors, and apoptosis in breast Cancer.
P53 gene mutations: case study of a clinical marker for solid tumors.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.

Schools

Thomas Jefferson University
Georgetown University Med Center

Procedures Preformed

Thoracentesis

Conditions Treated

Adrenal Gland Cancer
Anemia
Bladder Cancer
Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
View All

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Hospital

Mayo Clinic - Rochester, Minnesota

Drug Facts

NPI NUMBER		1750381679
NPPES Provider LastName		LIU
NPPES Provider FirstName		MINETTA
NPPES Provider ZIPCode		559050001
NPPES Provider State		MN
Specialty Description		Medical Oncology
Total Claim Count		108.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1750381679
Last Name Of The Provider	LIU
First Name Of The Provider	MINETTA
View All

Similar Doctors

	Dr. Harry H. Yoon, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles L. Loprinzi, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Sani H. Kizilbash, MD This Doctor is OpenDoctor Recommended.
	Dr. Prashant Kapoor, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Joleen M. Hubbard, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas M. Pisansky, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Timothy J. Hobday, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Axel F. Grothey, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Katharine A. Price, MD This Doctor is OpenDoctor Recommended.
	Dr. Larry R. Past, MD This Doctor is OpenDoctor Recommended.